Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions
LGND Stock Forecast
Ligand Pharmaceuticals stock forecast is as follows: an average price target of $126.00 (represents a 20.26% upside from LGND’s last price of $104.77) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
LGND Price Target
The average price target for Ligand Pharmaceuticals (LGND) is $126.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $144.00 to $90.00. This represents a potential 20.26% upside from LGND's last price of $104.77.
LGND Analyst Ratings
According to 5 Wall Street analysts, Ligand Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for LGND stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ligand Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 30, 2024 | Douglas Miehm | RBC Capital | $130.00 | $108.75 | 19.54% | 24.08% |
| Jul 09, 2024 | Matt Hewitt | Craig-Hallum | $140.00 | $86.88 | 61.14% | 33.63% |
| Jun 28, 2024 | Joseph Pantginis | H.C. Wainwright | $144.00 | $82.33 | 74.91% | 37.44% |
| Dec 23, 2022 | - | Roth Capital | $90.00 | $67.32 | 33.69% | -14.10% |
The latest Ligand Pharmaceuticals stock forecast, released on Jul 30, 2024 by Douglas Miehm from RBC Capital, set a price target of $130.00, which represents a 19.54% increase from the stock price at the time of the forecast ($108.75), and a 24.08% increase from LGND last price ($104.77).
Ligand Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 3 |
| Avg Price Target | - | $138.00 | $138.00 |
| Last Closing Price | $104.77 | $104.77 | $104.77 |
| Upside/Downside | -100.00% | 31.72% | 31.72% |
In the current month, the average price target of Ligand Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ligand Pharmaceuticals's last price of $104.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | Benchmark | Buy | Buy | Hold |
| Jul 30, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 30, 2024 | RBC Capital | Buy | Buy | Hold |
| Jul 30, 2024 | RBC Capital | - | Outperform | Initialise |
| Jul 09, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 23, 2022 | Roth Capital | Buy | Buy | Hold |
| Jul 05, 2022 | Barclays | Overweight | Overweight | Hold |
| Feb 22, 2022 | Benchmark | Buy | Buy | Hold |
| Feb 18, 2022 | Barclays | Overweight | Overweight | Hold |
Ligand Pharmaceuticals's last stock rating was published by Benchmark on Aug 12, 2024. The company gave LGND a "Buy" rating, the same as its previous rate.
Ligand Pharmaceuticals Financial Forecast
Ligand Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $28.10M | $32.87M | $26.37M | $43.98M | $50.38M | $66.09M | - | $45.69M | $72.47M | $64.83M | $84.67M | $55.15M | $69.99M | $41.85M | $41.42M | $33.16M | $27.00M | $24.81M | $24.99M | $43.48M | $59.59M | $45.66M |
| Avg Forecast | $60.50M | $44.50M | $39.10M | $31.70M | $42.14M | $38.97M | $33.04M | $27.92M | $25.64M | $27.22M | $24.74M | $33.55M | $44.09M | $38.32M | $37.73M | $34.21M | $65.09M | $58.74M | $71.41M | $62.91M | $56.68M | $45.09M | $29.96M | $26.53M | $24.90M | $22.36M | $21.01M | $38.28M | $42.76M | $35.63M |
| High Forecast | $73.56M | $54.10M | $47.54M | $38.54M | $51.24M | $40.18M | $40.17M | $33.95M | $25.92M | $33.10M | $30.08M | $40.79M | $53.61M | $46.59M | $37.73M | $36.55M | $69.53M | $62.75M | $76.28M | $67.21M | $60.55M | $48.17M | $32.00M | $28.35M | $26.60M | $23.89M | $22.45M | $40.89M | $51.32M | $42.75M |
| Low Forecast | $53.02M | $39.00M | $34.27M | $27.78M | $36.93M | $37.77M | $28.95M | $24.47M | $25.37M | $23.86M | $21.68M | $29.40M | $38.64M | $33.59M | $37.73M | $31.16M | $59.28M | $53.49M | $65.03M | $57.30M | $51.62M | $41.06M | $27.28M | $24.16M | $22.68M | $20.37M | $19.14M | $34.86M | $34.21M | $28.50M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 1.21% | 1.07% | 1.31% | 1.14% | 1.72% | - | 1.34% | 1.11% | 1.10% | 1.19% | 0.88% | 1.23% | 0.93% | 1.38% | 1.25% | 1.08% | 1.11% | 1.19% | 1.14% | 1.39% | 1.28% |
Ligand Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $27.92M, with a low forecast of $24.47M, and a high forecast of $33.95M. LGND's average Quarter revenue forecast represents a -0.63% decrease compared to the company's last Quarter revenue of $28.10M (Dec 23).
Ligand Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $-3.36M | $23.46M | $2.56M | $-16.79M | $-55.81M | $13.38M | - | $5.21M | $21.17M | $30.37M | $64.38M | $3.44M | $-11.07M | $7.40M | $12.78M | $7.32M | $-12.36M | $-1.61M | $-625.00K | $-795.55M | $36.63M | $96.15M |
| Avg Forecast | $352.21K | $259.06K | $227.63K | $184.54K | $245.32K | $226.89K | $192.34K | $6.03M | $149.29K | $158.49K | $144.02K | $5.48M | $256.68K | $32.00M | $219.68K | $4.33M | $6.39M | $25.30M | $50.04M | $18.57M | $20.07M | $-746.33K | $26.38M | $-10.09M | $20.21M | $-2.79M | $-726.22K | $222.85K | $-20.23M | $207.42K |
| High Forecast | $428.23K | $314.98K | $276.75K | $224.38K | $298.27K | $233.92K | $233.85K | $7.24M | $150.88K | $192.69K | $175.10K | $6.58M | $312.08K | $38.40M | $219.68K | $5.20M | $7.67M | $30.36M | $60.04M | $22.28M | $24.08M | $-597.06K | $31.65M | $-8.07M | $24.26M | $-2.23M | $-580.97K | $238.07K | $-16.18M | $248.90K |
| Low Forecast | $308.67K | $227.03K | $199.48K | $161.73K | $214.99K | $219.86K | $168.56K | $4.82M | $147.71K | $138.89K | $126.22K | $4.39M | $224.95K | $25.60M | $219.68K | $3.47M | $5.11M | $20.24M | $40.03M | $14.86M | $16.05M | $-895.59K | $21.10M | $-12.11M | $16.17M | $-3.35M | $-871.46K | $202.96K | $-24.27M | $165.93K |
| Surprise % | - | - | - | - | - | - | - | - | -22.49% | 148.01% | 17.81% | -3.06% | -217.42% | 0.42% | - | 1.20% | 3.31% | 1.20% | 1.29% | 0.19% | -0.55% | -9.92% | 0.48% | -0.73% | -0.61% | 0.57% | 0.86% | -3569.88% | -1.81% | 463.57% |
3 analysts predict LGND's average Quarter EBITDA for Dec 23 to be $149.29K, with a high of $150.88K and a low of $147.71K. This is -99.36% lower than Ligand Pharmaceuticals's previous annual EBITDA (Sep 23) of $23.46M.
Ligand Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $18.19M | $-12.79M | $2.29M | $41.95M | $-14.53M | $404.00K | - | $-15.38M | $-4.97M | $13.72M | $30.73M | $18.11M | $5.76M | $-6.70M | $22.09M | $-24.13M | $-7.37M | $-15.25M | $-14.42M | $666.34M | $-42.48M | $67.36M |
| Avg Forecast | $35.30M | $29.35M | $24.97M | $21.73M | $25.92M | $24.20M | $19.04M | $-24.00M | $11.91M | $11.18M | $11.47M | $-21.82M | $13.93M | $13.59M | $5.03M | $-17.25M | $-3.07M | $10.74M | $30.46M | $13.62M | $5.12M | $-6.29M | $15.11M | $-15.72M | $-6.56M | $-18.25M | $-11.01M | $574.88M | $-25.77M | $48.40M |
| High Forecast | $45.20M | $37.58M | $31.97M | $27.83M | $33.20M | $30.99M | $24.38M | $-19.20M | $15.25M | $14.31M | $14.68M | $-17.46M | $17.84M | $16.31M | $5.03M | $-13.80M | $-2.46M | $12.89M | $36.55M | $16.34M | $6.15M | $-5.03M | $18.13M | $-12.58M | $-5.25M | $-14.60M | $-8.81M | $689.85M | $-20.61M | $58.08M |
| Low Forecast | $29.63M | $24.63M | $20.96M | $18.24M | $21.76M | $20.31M | $15.98M | $-28.80M | $10.00M | $9.38M | $9.62M | $-26.19M | $11.69M | $10.87M | $5.03M | $-20.70M | $-3.69M | $8.59M | $24.37M | $10.90M | $4.10M | $-7.55M | $12.09M | $-18.87M | $-7.87M | $-21.90M | $-13.21M | $459.90M | $-30.92M | $38.72M |
| Surprise % | - | - | - | - | - | - | - | - | 1.53% | -1.14% | 0.20% | -1.92% | -1.04% | 0.03% | - | 0.89% | 1.62% | 1.28% | 1.01% | 1.33% | 1.13% | 1.07% | 1.46% | 1.53% | 1.12% | 0.84% | 1.31% | 1.16% | 1.65% | 1.39% |
Ligand Pharmaceuticals's average Quarter net income forecast for Mar 24 is $-24.00M, with a range of $-28.80M to $-19.20M. LGND's average Quarter net income forecast represents a -231.97% decrease compared to the company's last Quarter net income of $18.19M (Dec 23).
Ligand Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $15.99M | $14.66M | $11.29M | $10.86M | $31.13M | $17.45M | - | $18.18M | $17.74M | $12.72M | $14.71M | $12.62M | $30.08M | $15.02M | $10.07M | $9.26M | $10.28M | $9.53M | $10.99M | $11.09M | $11.16M | $9.63M |
| Avg Forecast | $20.09M | $14.78M | $12.98M | $10.53M | $13.99M | $12.94M | $10.97M | $9.27M | $8.52M | $9.04M | $8.21M | $25.79M | $14.64M | $12.60M | $12.53M | $20.38M | $10.97M | $9.96M | $14.58M | $9.49M | $26.74M | $14.10M | $6.89M | $6.04M | $9.15M | $11.40M | $8.40M | $9.57M | $6.77M | $6.92M |
| High Forecast | $24.43M | $17.97M | $15.79M | $12.80M | $17.01M | $13.34M | $13.34M | $11.27M | $8.61M | $10.99M | $9.99M | $30.94M | $17.80M | $15.11M | $12.53M | $24.46M | $13.16M | $11.95M | $17.50M | $11.39M | $32.09M | $16.92M | $8.27M | $7.24M | $10.98M | $13.68M | $10.07M | $11.48M | $8.13M | $8.30M |
| Low Forecast | $17.61M | $12.95M | $11.38M | $9.23M | $12.26M | $12.54M | $9.61M | $8.13M | $8.43M | $7.92M | $7.20M | $20.63M | $12.83M | $10.08M | $12.53M | $16.31M | $8.78M | $7.97M | $11.67M | $7.59M | $21.39M | $11.28M | $5.51M | $4.83M | $7.32M | $9.12M | $6.72M | $7.65M | $5.42M | $5.54M |
| Surprise % | - | - | - | - | - | - | - | - | 1.88% | 1.62% | 1.37% | 0.42% | 2.13% | 1.39% | - | 0.89% | 1.62% | 1.28% | 1.01% | 1.33% | 1.13% | 1.07% | 1.46% | 1.53% | 1.12% | 0.84% | 1.31% | 1.16% | 1.65% | 1.39% |
Ligand Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $9.27M, based on 1 Wall Street analysts, with a range of $8.13M to $11.27M. The forecast indicates a -42.02% fall compared to LGND last annual SG&A of $15.99M (Dec 23).
Ligand Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 1 | 2 | 2 | 2 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 8 |
| EPS | - | - | - | - | - | - | - | - | $1.03 | $-0.74 | $0.13 | $2.46 | $-0.86 | $0.02 | - | $-0.91 | $-0.30 | $0.82 | $1.84 | $1.10 | $0.36 | $-0.42 | $1.38 | $-1.46 | $-0.43 | $-0.81 | $-0.74 | $32.59 | $-2.02 | $3.19 |
| Avg Forecast | $1.96 | $1.63 | $1.39 | $1.21 | $1.44 | $1.34 | $1.06 | $0.83 | $0.66 | $0.62 | $0.64 | $0.89 | $0.77 | $0.28 | $0.28 | $0.42 | $0.88 | $0.68 | $0.89 | $0.73 | $0.70 | $0.63 | $0.49 | $0.42 | $0.41 | $0.39 | $0.35 | $19.28 | $0.74 | $0.74 |
| High Forecast | $2.51 | $2.08 | $1.77 | $1.54 | $1.84 | $1.72 | $1.35 | $1.07 | $0.85 | $0.79 | $0.81 | $1.14 | $0.99 | $0.36 | $0.28 | $0.46 | $0.96 | $0.74 | $0.97 | $0.79 | $0.77 | $0.69 | $0.53 | $0.46 | $0.45 | $0.43 | $0.39 | $21.00 | $0.89 | $0.89 |
| Low Forecast | $1.64 | $1.37 | $1.16 | $1.01 | $1.21 | $1.13 | $0.89 | $0.70 | $0.55 | $0.52 | $0.53 | $0.75 | $0.65 | $0.23 | $0.28 | $0.37 | $0.78 | $0.60 | $0.79 | $0.64 | $0.62 | $0.56 | $0.43 | $0.37 | $0.37 | $0.35 | $0.31 | $17.05 | $0.59 | $0.59 |
| Surprise % | - | - | - | - | - | - | - | - | 1.56% | -1.19% | 0.20% | 2.75% | -1.11% | 0.07% | - | -2.15% | -0.34% | 1.20% | 2.06% | 1.52% | 0.51% | -0.66% | 2.81% | -3.45% | -1.04% | -2.06% | -2.09% | 1.69% | -2.73% | 4.31% |
According to 1 Wall Street analysts, Ligand Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.83, with a low estimate of $0.70 and a high estimate of $1.07. This represents a -19.03% decrease compared to LGND previous annual EPS of $1.03 (Dec 23).
Ligand Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| RCUS | Arcus Biosciences | $17.95 | $35.20 | 96.10% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| ORIC | ORIC Pharmaceuticals | $9.89 | $17.00 | 71.89% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| BGNE | BeiGene | $198.49 | $247.75 | 24.82% | Buy |
| LGND | Ligand Pharmaceuticals | $104.77 | $126.00 | 20.26% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
LGND Forecast FAQ
Is Ligand Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Ligand Pharmaceuticals (LGND) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of LGND's total ratings.
What is LGND's price target?
Ligand Pharmaceuticals (LGND) average price target is $126 with a range of $90 to $144, implying a 20.26% from its last price of $104.77. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ligand Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for LGND stock, the company can go up by 20.26% (from the last price of $104.77 to the average price target of $126), up by 37.44% based on the highest stock price target, and down by -14.10% based on the lowest stock price target.
Can Ligand Pharmaceuticals stock reach $200?
LGND's average twelve months analyst stock price target of $126 does not support the claim that Ligand Pharmaceuticals can reach $200 in the near future.
What are Ligand Pharmaceuticals's analysts' financial forecasts?
Ligand Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $142.08M (high $165.54M, low $128.12M), average EBITDA is $6.69M (high $8M, low $5.43M), average net income is $45.16M (high $69.37M, low $29.24M), average SG&A $47.18M (high $54.97M, low $42.54M), and average EPS is $4.67 (high $5.98, low $3.92). LGND's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $175.8M (high $213.74M, low $154.07M), average EBITDA is $1.02M (high $1.24M, low $896.91K), average net income is $111.35M (high $142.59M, low $93.45M), average SG&A $58.38M (high $70.98M, low $51.16M), and average EPS is $6.18 (high $7.91, low $5.18).
Did the LGND's actual financial results beat the analysts' financial forecasts?
Based on Ligand Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $131.31M, beating the average analysts forecast of $111.16M by 18.13%. Apple's EBITDA was $11.94M, beating the average prediction of $5.93M by 101.26%. The company's net income was $52.15M, beating the average estimation of $12.73M by 309.56%. Apple's SG&A was $52.79M, beating the average forecast of $51.56M by 2.39%. Lastly, the company's EPS was $2.94, beating the average prediction of $2.81 by 4.60%. In terms of the last quarterly report (Dec 2023), Ligand Pharmaceuticals's revenue was $28.1M, beating the average analysts' forecast of $25.64M by 9.58%. The company's EBITDA was $-3.358M, missing the average prediction of $149.3K by -2349.24%. Ligand Pharmaceuticals's net income was $18.19M, beating the average estimation of $11.91M by 52.69%. The company's SG&A was $15.99M, beating the average forecast of $8.52M by 87.79%. Lastly, the company's EPS was $1.03, beating the average prediction of $0.661 by 55.88%